GlassScriptPhysician profile
William S Digiacomo
NPI 1982652970
$7,059.50
in general payments reported to CMS, 2019-2025
38 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $751 · 2021: $906 · 2022: $1,389 · 2023: $1,337 · 2024: $844 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,445.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,776.77 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,512.10 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Pfizer INC. | $363.99 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $357.85 | 2020-2024 | Trulance, Xifaxan, Plenvu |
| Janssen Biotech, INC. | $347.81 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $334.56 | 2020-2025 | Mounjaro, Jardiance, Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.94 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $261.26 | 2019-2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $256.95 | 2020-2025 | Entyvio |
| Madrigal Pharmaceuticals | $184.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $157.24 | 2020-2023 | |
| Abbott Laboratories | $155.95 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $103.88 | 2020-2023 | |
| Nevro Corp. | $101.30 | 2022-2023 | Senza |
| Astrazeneca Pharmaceuticals LP | $72.97 | 2019-2024 | Farxiga |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Digiacomo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.